These results are in accordance with other studies, which observed a reduced expression of P2RY12 in active inflammatory lesions in MS patients (Beaino et al., 2017; Mildner et al., 2017; Zrzavy et al., 2017). The gene discussed is P2RY12; the disease is myeloid sarcoma.